Serum levels of KL-6 are useful biomarkers for severe radiation pneumonitis

Lung Cancer

Volumn 34, Issue 1, 2001, Pages 141-148

  Goto, Koichi ^a,c   Kodama, Tetsuro ^b   Sekine, Ikuo ^b   Kakinuma, Ryutaro ^a   Kubota, Kaoru ^a   Hojo, Fumihiko ^a   Matsumoto, Taketoshi ^a   Ohmatsu, Hironobu ^a   Ikeda, Hiroshi ^a   Ando, Masayuki ^c   Nishiwaki, Yutaka ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

KL 6; Lung cancer; Radiation pneumonitis; Radiotherapy

Indexed keywords

ANTIINFECTIVE AGENT; GLYCOPROTEIN; STEROID HORMONE;

ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; EVALUATION; HUMAN; LUNG ALVEOLUS CELL; LUNG CANCER; MONITORING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION INJURY; RADIATION PNEUMONIA; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0034848063     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00215-X     Document Type: Article

References (30)

1. Concurrent radiotherapy and chemotherapy for locally advanced non-small-cell cancer of the lung. Report of a clinical trial and review of the literature
2. Latent radiation injury of lungs or heart activated by steroid withdrawal
3. Pulmonary toxicity after radiation and bleomycin: A review
4. Serum lactic dehydrogenase activity and diffuse interstitial pneumonitis
5. Diagnostic usefulness of KL-6 measurements in patients with pulmonary complications after administration of amiodarone
6. The pulmonary toxicity of antineoplastic agents
7. Pulmonary effects of radiation therapy
8. Monitoring of serum KL-6 antigen in a patient with radiation pneumonia
9. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: A randomized trial of the North Central Cancer Treatment Group
10. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: A randomized trial of the Southeastern Cancer Study Group
11. Neoadjuvant cisplatin plus vinblastine chemotherapy in locally advanced non-small cell lung cancer
12. Serum type III procollagen peptide concentration in cryptogenic fibrosing alveolitis and its clinical relevance
13. KL-6: A serum marker for interstitial pneumonia
14. Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma
15. KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease
16. Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer
17. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6
18. Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer
19. Prediction of future cancer mortality in Japan
20. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy
21. Quantitative effect of combined chemotherapy and fractionated radiotherapy on the incidence of radiation-induced lung damage: A prospective clinical study
22. Concurrent chemotherapy/radiotherapy for limited small cell lung carcinoma
23. Pulmonary radiation injury
24. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer
25. Levels of serum KL-6 in a patient with drug-induced pneumonitis
26. Quantification of combined radiation therapy and chemotherapy effects on critical normal tissues
27. Radiation pneumonitis following combined modality therapy for lung cancer: Analysis of prognostic factors
28. Results of combination chemotherapy and thoracic radiation therapy for unresectable non-small cell carcinoma of the lung
29. Significance of serum type III procollagen N4erminal peptide in patients with fibrotic lung disease
30. Thoracic irradiation in Hodgkin's disease: Disease control and long-term complications